Freeman Spogli Institute for International Studies Center for Health Policy/Center for Primary Care and Outcomes Research Stanford University


People of CHP/PCOR


Photo of Mark Hlatky
Magnify

Mark A. Hlatky, MD   Download vCard

Professor of Health Research and Policy and of Medicine (Cardiovascular Medicine) and CHP/PCOR Fellow

Department of Health Research and Policy
Stanford University
Redwood Bldg, T150A
Stanford, CA 94305-5405

hlatky@stanford.edu
(650) 723 723-6426 6426 (voice)
(650 650) 725 725-6951 6951 (fax)


Research Interests
outcomes research, clinical trials, cost-effectiveness


Mark Hlatky is a professor of Health Research and Policy and of medicine (cardiovascular medicine) at Stanford, as well as a CHP/PCOR fellow. His major interests are in outcomes research, evidence-based medicine, and cost-effectiveness analysis. He introduced data collection about economic and quality of life endpoints in several randomized trials, principally trials of therapies for cardiovascular disease.

Hlatky received his MD from the University of Pennsylvania, and, after residency at the University of Arizona, studied as a Robert Wood Johnson Clinical Scholar at the University of California, San Francisco. He trained in cardiology at Duke University Medical Center, and then joined the Duke faculty. He has been at the Stanford University School of Medicine since 1989, where he is currently professor and chair of Health Research and Policy.

Stanford Departments
Health Research and Policy



Publications

The 5 most recent are displayed. More publications »



Events & Presentations



Research Programs & Projects




News around the web

Angioplasty Vs Drugs for Diabetics
Says Dr Mark Hlatky of Stanford university ?For patients with relatively mild symptoms of heart disease, angioplasty is clearly more expensive and it's ...
November 21, 2009 in Daily News Trends

Drugs Provide Same Benefit as Angioplasty for Diabetics, at Lower Cost
... not more beneficial," Mark Hlatky, MD, professor of health research and policy and cardiovascular medicine at Stanford University, was quoted as saying.
November 20, 2009 in Ivanhoe

Diabetic Patients With Heart Disease Benefit More from Drug Therapy Than ...
A new National Institutes of Health study led by Stanford University School of Medicine researcher Mark Hlatky, MD has said that many patients with diabetes ...
November 20, 2009 in MedIndia

BARI 2D cost-effectiveness analysis favors medication over PCI for less severe ...
A summary of the economic analysis of the BARI 2D trial was presented by Dr Mark Hlatky (Stanford University, CA) at the American Heart Association (AHA) ...
November 18, 2009 in TheHeart.Org

Drug therapy offers substantial cost savings than angioplasty
... take medicine instead, according to a new National Institutes of Health study led by Stanford University School of Medicine researcher Mark Hlatky, MD.
November 18, 2009 in News-Medical.net